New Migraine Medication Options for Treatment and Prevention

The migraine treatment landscape has changed more in the past several years than in the previous three decades, largely because researchers identified a single molecule at the center of migraine attacks and built drugs around it. That molecule, calcitonin gene-related peptide (CGRP), is now the target of two entirely new drug classes available for both stopping attacks and preventing them. For people who have cycled through older medications with limited success or intolerable side effects, these newer options represent genuinely different approaches rather than minor variations on existing therapies.

Why CGRP Changed Everything

CGRP is a small signaling molecule concentrated in the nerve fibers that relay pain signals from the head and face to the brain. During a migraine attack, CGRP floods out of nerve endings around the brain’s blood vessels, triggering a chain reaction: blood vessels dilate, surrounding tissues become inflamed, and the pain-sensing nerves grow increasingly sensitive to stimuli that would not normally hurt.¹ Injecting CGRP into people with migraine can actually trigger migraine-like symptoms, which was early proof that the molecule was not just present during attacks but actively driving them.² That understanding opened the door to drugs designed specifically to block CGRP or its receptor, rather than borrowing medications originally developed for blood pressure, seizures, or depression.

Gepants for Acute Attacks

Gepants are small-molecule drugs that block the CGRP receptor, essentially preventing the pain signal from being received. Two oral gepants were approved for acute migraine treatment: ubrogepant in late 2019 and rimegepant in 2020.³ Both relieve pain quickly and, critically, do not constrict blood vessels the way triptans do. That matters because triptans, while effective, are off-limits for people with heart disease, stroke history, or uncontrolled vascular risk factors.

In long-term follow-up of ubrogepant over a year, roughly a quarter of treated attacks resulted in complete pain freedom within two hours at the higher dose, and about two-thirds of attacks saw meaningful pain relief in that window. Those numbers jumped substantially when people took the drug early, while the headache was still mild: pain freedom within two hours roughly doubled compared to waiting until the headache was moderate or severe.³ That “treat early” pattern is familiar from triptans, but it is reassuring to see confirmed in a drug class with a different mechanism.

Rimegepant stands out for a different reason: it is the first migraine drug approved for both acute treatment and prevention. Taken as needed, it relieves active attacks. Taken every other day on a regular schedule, it reduces the number of migraine days per month.⁴ For someone who needs both acute and preventive therapy, a single medication covering both roles simplifies treatment considerably.

Lasmiditan and the Ditan Class

Lasmiditan works through a completely different receptor than either triptans or gepants. It activates a specific serotonin receptor subtype found on nerve terminals, which reduces CGRP release and calms the overactive pain circuits without narrowing blood vessels at all.⁵ Its approval was significant in part because it proved that vasoconstriction is not actually necessary to stop a migraine, a question that had lingered since triptans were introduced.⁶

The trade-off is that lasmiditan can cause dizziness, drowsiness, and a feeling of heaviness or tingling. You should not drive for at least eight hours after taking it, which limits its usefulness during a workday. It fills an important gap for people who cannot safely take triptans, but it is not a drop-in replacement for everyone.

Preventive Medications That Target CGRP Directly

Prevention is where the CGRP-targeted revolution has arguably made the biggest difference. Four injectable monoclonal antibodies are now approved that either bind CGRP itself or block its receptor. They are given monthly or quarterly by injection and are specifically designed for migraine prevention. In a network meta-analysis of large clinical trials, virtually all of these antibodies and their doses significantly reduced monthly migraine days compared to placebo.⁷ They also tend to be better tolerated than older preventives like topiramate, beta-blockers, or antidepressants, which were borrowed from other fields and brought side effects like weight gain, cognitive fog, or fatigue.⁸

On the oral preventive side, atogepant is a gepant taken daily as a pill. In a large trial of episodic migraine, the highest dose reduced migraine days by about four per month compared to roughly two and a half for placebo, a meaningful difference of about one and a half fewer migraine days attributable to the drug.⁹ For chronic migraine, the effect was even more pronounced: atogepant reduced monthly migraine days by about seven to seven and a half, compared to about five for placebo.¹⁰ Having an oral daily option matters for people who prefer pills to injections or who want to avoid the commitment of a monthly shot.

What About People Who Have Tried Everything Else

A major selling point of CGRP-targeted therapies is their track record in people with “treatment-resistant” migraine, meaning those who have failed multiple prior preventives. In real-world studies of patients with resistant chronic migraine, anti-CGRP antibodies reduced headache frequency by about nine days per month after twelve weeks, and over half of patients achieved at least a 50% reduction in monthly migraine days.¹¹ Some patients even reverted from chronic migraine to episodic migraine, crossing back below the threshold of fifteen headache days per month.¹² Disability scores often improved even more dramatically than headache frequency alone, suggesting that the quality of remaining headaches also changed for the better.¹³

Combining Anti-CGRP Drugs with Botox

For chronic migraine that does not respond adequately to a single preventive, clinicians have started combining anti-CGRP monoclonal antibodies with onabotulinumtoxinA (Botox), which has been used for chronic migraine prevention for over a decade. The rationale is that the two drugs hit CGRP from different angles: Botox reduces CGRP release from nerve terminals, while the antibody mops up the CGRP that does get released or blocks its receptor.¹⁴

Real-world data from patients who added an anti-CGRP antibody on top of Botox showed that monthly migraine days dropped from a median of fifteen to eight, a substantial improvement over either therapy alone. About two-thirds of patients on the combination achieved at least a 50% reduction in migraine days.¹⁵ In another cohort, over 60% hit that same benchmark after three months of combination treatment, and serious side effects were absent, with constipation and mild injection-site reactions being the most common complaints.¹⁶ This combination is still not formally studied in the kind of large randomized trial that would make it a standard guideline recommendation, but the accumulating clinical experience is encouraging for people stuck in the hardest-to-treat category.

Medication Overuse Risk With the Newer Drugs

One of the ugliest paradoxes in headache medicine is medication overuse headache, where taking acute pain medications too frequently transforms episodic migraine into a near-daily problem. This is well-documented with triptans, opioids, and over-the-counter painkillers. A natural question is whether gepants and lasmiditan carry the same risk.

Animal studies offer some reassurance for gepants: when rats were given the CGRP receptor blocker olcegepant on a regular basis, they did not develop the increased pain sensitivity that characterizes overuse headache.¹⁷ Lasmiditan was a different story. In the same experimental models, persistent exposure to the 5-HT1F receptor agonist produced increased pain sensitivity and changes in nerve fibers similar to what is seen with triptans.¹⁸ These are animal data, not confirmed human findings, but they suggest that gepants may carry an inherently lower overuse risk than either triptans or lasmiditan. That is one reason some clinicians are comfortable with rimegepant’s every-other-day preventive dosing schedule.

Long-Term Safety and Blood Pressure Concerns

CGRP is not only active in migraine circuits. It is a potent vasodilator throughout the body, which led to early worries that blocking it long-term could raise blood pressure or increase cardiovascular risk. A meta-analysis of long-term studies found that only about 3% of patients discontinued anti-CGRP antibodies because of side effects, and the rate of side-effect-related dropout stayed below 5% even beyond the first year of treatment.¹⁹

The blood pressure picture is more nuanced. A prospective study found that patients starting anti-CGRP antibodies experienced modest but statistically real increases in blood pressure, with systolic readings climbing by about 5 mmHg on average. A small percentage of patients with previously normal blood pressure needed to start blood pressure medication after beginning erenumab.²⁰ A larger Veterans Health Administration study added context: among patients without pre-existing high blood pressure, the rate of developing hypertension was similar whether they took an anti-CGRP drug or topiramate. But among patients who already had hypertension, those on anti-CGRP treatment needed slightly more blood pressure medication over time.²¹ A systematic review concluded that while the benefits of these drugs for migraine prevention are substantial, clinicians should monitor blood pressure regularly, especially in patients with existing cardiovascular risk.²²

Pregnancy, Children, and Other Special Situations

Migraine is most common during reproductive years, which means pregnancy is a constant practical concern. No CGRP-targeted drug is formally approved for use during pregnancy, and large controlled trials in pregnant women do not exist for obvious ethical reasons. What we do have are safety-signal analyses from global adverse-event databases. When researchers compared pregnancy-related safety reports for CGRP-targeting drugs against triptans, they found no signal of increased risk: adverse pregnancy outcomes and fetal or neonatal problems were reported at similar or lower rates than with triptans.²³ A separate analysis specifically of the monoclonal antibodies found no distinct patterns of maternal or fetal toxicity, and spontaneous abortion was not reported disproportionately compared to the broader database.²⁴ These findings are reassuring but preliminary. The current standard of care remains to stop CGRP-targeted drugs before planned pregnancy, though accidental exposure does not appear to be catastrophic based on the data so far.

In children and adolescents, the evidence is even thinner. CGRP-targeted drugs are not yet approved for pediatric use, but a small case series of children with severe daily headaches who had failed other treatments showed dramatic improvements in disability scores and no significant side effects with anti-CGRP antibodies.²⁵ Pediatric trials are underway, and this space is likely to expand in the coming years.

Insurance Barriers and Step Therapy

The medications described here are expensive, and getting insurance to pay for them is a real obstacle. While coverage for at least one CGRP-targeted medication is now fairly widespread, individual drug coverage varies. A 2024 analysis of nearly 150 insurance plans found that while about 95% covered at least one CGRP drug, specific medications had much lower coverage: galcanezumab was covered by about 85% of plans, but atogepant by only around 62%.²⁶ More frustratingly, most plans still required “step therapy,” meaning you have to try and fail older, cheaper medications before the insurer will approve a CGRP drug. This persisted even after the American Headache Society released a consensus statement recommending earlier access. If your doctor recommends one of these medications and your insurance initially denies it, an appeal with documentation of prior treatment failures often succeeds, but it adds delay and effort to an already exhausting condition.

When CGRP Drugs Do Not Work

For all their promise, CGRP-targeted therapies do not help everyone. Roughly 40% of patients do not respond to them.²⁷ Researchers suspect that in these non-responders, migraine is being driven by a different signaling pathway. One leading candidate is PACAP (pituitary adenylate cyclase-activating polypeptide), a molecule with several parallels to CGRP: it is found in sensory nerve fibers, it dilates blood vessels in the head, and infusing it into migraine patients can trigger attacks. Studies in animal models have shown that the PACAP pathway operates independently of CGRP, meaning blocking one does not block the other.²⁸ Antibodies and small molecules targeting PACAP are now in early development. If they pan out, they could become the next-line therapy for the substantial group left behind by CGRP drugs.

Other experimental targets include ion channels on nerve cells that act as pain amplifiers. Certain channels seem to regulate how much CGRP gets released in the first place, and laboratory work suggests that drugs that modulate these channels could dampen the entire inflammatory cascade.²⁹ Some of these ion channel modulators already exist as approved drugs for other conditions like epilepsy, which could shorten the path to clinical testing for migraine.³⁰

Can a Blood Test Predict Who Will Respond

One of the frustrations with current treatment is that there is no reliable way to know in advance whether a specific CGRP-targeted drug will work for you. Researchers have explored whether measuring CGRP levels in the blood before treatment could serve as a predictor. Results have been mixed and sometimes counterintuitive. One study found that higher baseline CGRP levels were actually associated with a poorer response to anti-CGRP antibodies over six months, particularly in chronic migraine, where elevated CGRP predicted more residual migraine days and disability.³¹ Meanwhile, a trial that tried to use sensitivity to infused CGRP as a predictor of erenumab response concluded that it could not reliably distinguish future responders from non-responders.³² For now, the honest answer is that we do not have a test that can tell you which drug will work before you try it. Researchers continue to investigate other biological markers, including genetic and metabolic profiles, but clinically useful prediction tools remain a work in progress.³³

How to Think About Choosing Among These Options

If you are newly considering one of these medications, the practical decision tree tends to follow a few branching points. For acute treatment, triptans remain first-line if you tolerate them and have no cardiovascular contraindications. If triptans are off the table because of heart or vascular issues, lasmiditan and gepants both become options, with gepants carrying the advantage of no driving restriction and potentially lower medication-overuse risk. For prevention, the choice between injectable antibodies and oral gepants often comes down to preference: some people like the simplicity of a monthly injection they do not have to think about daily, while others prefer a pill. And if you need both acute and preventive therapy, rimegepant’s dual approval means a single drug can cover both roles.

For people with chronic migraine that has not budged with a single preventive, the combination of Botox plus an anti-CGRP antibody is increasingly used in headache clinics. And for anyone who does not respond to any CGRP-targeted approach, the pipeline of PACAP-targeting drugs and ion channel modulators offers genuine reasons for optimism that the next generation of options is on its way.